FTC Files Amicus Brief in Antitrust Case, Accusing J&J of Illegal Monopoly
JNJ sits 59% above its 52-week low of $149.74.
Summary
The Federal Trade Commission (FTC) has filed an amicus brief in an antitrust case, supporting allegations that Johnson & Johnson illegally maintained a monopoly through anticompetitive conduct. This introduces a new, significant regulatory and legal challenge for J&J, which is already managing multiple ongoing legal issues, including talc litigation and patent disputes. An antitrust finding could result in substantial fines, forced divestitures, or mandated changes to business practices, potentially impacting the company's long-term market structure and profitability.
At the time of this announcement, JNJ was trading at $237.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $572.2B. The 52-week trading range was $149.74 to $251.71. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.